Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase III NCT05072314

Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial

Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial — Recruiting • Phase III • Oncology • NCT05072314.

📅 25 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase III
NCT ID
NCT05072314
Sponsor
Monash University
Start
2022-07-27
ClinicaliQ Trial Snapshot
  • Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial — Recruiting • Phase III • Oncology • NCT05072314.
  • The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.
  • Sponsor: Monash University.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.

Eligibility Snapshot
  • : * Consenting adult female patients (≥18 years) undergoing mastectomy (unilateral or bilateral) or breast conserving surgery (unilateral or bilateral) for the primary excision of confirmed or suspected primary breast cancer under general anaesthesia (including those with simultaneous insertion of tissue expanders or implants)*. * this specifically excludes patients undergoing surgery for locoregional recurrence * American Society of Anaesthesiologist (ASA) physical scale 1-3

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
Oncology · 17 Mar 2026
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes -…
View guideline →
Clinical Brief
University explores endometriosis and cancer link
Oncology · BBC Health · 08 May 2026
Endometriosis affects approximately 10% of UK women and remains associated with significant morbidity including chronic pain and reduced fertility Research is investigating…
View brief →
Guideline
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Oncology · 21 Apr 2026
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant…
View guideline →
Guideline
Melanoma: Assessment and Management (NICE NG14)
Oncology · 27 Mar 2026
Excise primary melanomas with 2 cm margins if Breslow thickness ≤2 mm, or 1–2 cm margins if >2 mm, tailored to tumour…
View guideline →
Clinical Brief
Ultrasound delays putting pregnant women and cancer patients at risk, sonographers say
Oncology · BBC Health · 28 Mar 2026
Ultrasound service capacity is insufficient due to inadequate sonographer training, creating delays that compromise care for pregnant women and cancer patients requiring…
View brief →
Guideline
Oesophago-Gastric Cancer: Assessment and Management (NICE NG83)
Oncology · 27 Mar 2026
Multimodal treatment with neoadjuvant chemotherapy followed by surgical resection improves survival for locally advanced oesophago-gastric junction and gastric adenocarcinomas. HER2 testing is…
View guideline →